NO20045680L - Bakterietransformerende middel - Google Patents

Bakterietransformerende middel

Info

Publication number
NO20045680L
NO20045680L NO20045680A NO20045680A NO20045680L NO 20045680 L NO20045680 L NO 20045680L NO 20045680 A NO20045680 A NO 20045680A NO 20045680 A NO20045680 A NO 20045680A NO 20045680 L NO20045680 L NO 20045680L
Authority
NO
Norway
Prior art keywords
bacterial strain
unsubstituted
alkenyl
substituted
alkynyl
Prior art date
Application number
NO20045680A
Other languages
English (en)
Norwegian (no)
Inventor
Michael Ernest Levey
Robert Leslie Hill
Original Assignee
Pharmaceutica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmaceutica Ltd filed Critical Pharmaceutica Ltd
Publication of NO20045680L publication Critical patent/NO20045680L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20045680A 2002-05-31 2004-12-28 Bakterietransformerende middel NO20045680L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0212622.5A GB0212622D0 (en) 2002-05-31 2002-05-31 Bacterial transforming agent
PCT/GB2003/002402 WO2003101488A1 (en) 2002-05-31 2003-06-02 Bacterial transforming agent

Publications (1)

Publication Number Publication Date
NO20045680L true NO20045680L (no) 2005-02-28

Family

ID=9937806

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045680A NO20045680L (no) 2002-05-31 2004-12-28 Bakterietransformerende middel

Country Status (13)

Country Link
US (1) US20060040871A1 (https=)
EP (1) EP1553981A1 (https=)
JP (1) JP2006504404A (https=)
AU (1) AU2003232352A1 (https=)
BR (1) BR0311482A (https=)
CA (1) CA2487597A1 (https=)
EA (1) EA007093B1 (https=)
GB (1) GB0212622D0 (https=)
IL (1) IL165433A0 (https=)
MX (1) MXPA04011879A (https=)
NO (1) NO20045680L (https=)
NZ (1) NZ537447A (https=)
WO (1) WO2003101488A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009036121A1 (en) * 2007-09-12 2009-03-19 Targanta Therapeutics Corp. Method of inhibiting clostridium difficile by administration of oritavancin
AU2010313228B2 (en) * 2009-10-30 2014-05-29 Biogenic Innovations, Llc Methylsulfonylmethane (MSM) for treatment of drug resistant microorganisms
US9839609B2 (en) 2009-10-30 2017-12-12 Abela Pharmaceuticals, Inc. Dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) formulations to treat osteoarthritis
DE102010013587A1 (de) * 2010-03-31 2011-10-06 Heliolux Gmbh N-(Aminoacyl)-Amino-Ester
WO2012106469A2 (en) * 2011-02-01 2012-08-09 New York University Methods for treating infections by targeting microbial h2s-producing enzymes
HRP20200101T1 (hr) 2014-11-06 2020-04-03 Xellia Pharmaceuticals Aps Glikopeptidni pripravci
US10829440B2 (en) 2015-06-12 2020-11-10 Brown University Antibacterial compounds and methods of making and using same
WO2018237268A1 (en) * 2017-06-22 2018-12-27 Brown University Novel antibacterial compounds and methods of making and using same
US11555010B2 (en) 2019-07-25 2023-01-17 Brown University Diamide antimicrobial agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834430A (en) * 1995-05-31 1998-11-10 Biosynth S.R.L. Potentiation of antibiotics
US6569830B1 (en) * 1999-03-05 2003-05-27 Ambi, Inc. Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains

Also Published As

Publication number Publication date
US20060040871A1 (en) 2006-02-23
BR0311482A (pt) 2005-03-15
GB0212622D0 (en) 2002-07-10
EA007093B1 (ru) 2006-06-30
JP2006504404A (ja) 2006-02-09
EA200401589A1 (ru) 2005-06-30
CA2487597A1 (en) 2003-12-11
MXPA04011879A (es) 2005-09-12
IL165433A0 (en) 2006-01-15
EP1553981A1 (en) 2005-07-20
WO2003101488A1 (en) 2003-12-11
NZ537447A (en) 2006-12-22
AU2003232352A1 (en) 2003-12-19

Similar Documents

Publication Publication Date Title
NO20070984L (no) Dihydropterididinon infusjonslosning som har en lang lagringstid
CA2192255C (en) Treatment of chlamydia infectious diseases by rifamycin derivative
NO20071617L (no) Indozolonderivater som 11B-HSD1-inhibitorer
NO20052914L (no) Terapeutiske forbindelser
NO20045680L (no) Bakterietransformerende middel
JO2282B1 (en) Oxazole derivatives
NO20064456L (no) Thiadiazolidinoner som GSK-3 inhibitorer
RU2009102832A (ru) С-фенил-1-тилоглюцитолы
NO20050134L (no) Difenylazetidioner substituert med syregrupper, fremgangsmate for fremstilling av disse, medikamenter inneholdende disse forbindelser og deres anvendelse
NO20065926L (no) Substituerte oksazolbenzoisotiazoldioksidderivater samt fremgangsmate for fremstilling og anvendelse derav
CA2336412A1 (en) Medicament for treatment of diabetes
NO984878L (no) Fremstilling og anvendelse som medikamenter av 3-alkoksypyridin-2-karboksylsyreamidestere
NO20053133L (no) Kjemiske forbindelser.
NO20053467L (no) Fremgangsmate ved biotransformasjon av kolkionforbindelser til de tilsvarende 3-glykosyl-derivater
ES2098947T3 (es) Derivados de beta,beta-dimetil-4-piperidinoetanamina como inhibidores de la biosintesis del colesterol.
NO20082727L (no) Salter av 9-oksoakridin-10-eddiksyre med 1-alkylamino-1-deoksypolyoler
NO20054669L (no) Substituerte kinobenzoxazinanaloger
EA200800303A1 (ru) Применение производных и аналогов тиазола при нарушениях, вызванных свободными жирными кислотами
NO20060114L (no) Naftylenderivater som cytokrom P450-inhibitorer
GB0205688D0 (en) Chemical compounds
NO20050667L (no) N-substituerte-1H-indol-5-propionsyreforbindelser som PPAR agonister nyttige for behandling av diabetes
MY143576A (en) Chiral derivatives of 3-phenyl-propionic acid, particularly useful for the treatment of diseases associated with ppar-alpha or ppar-gamma
NO20081220L (no) Nytt cercosporamidderivat
NO20051901L (no) Nye antimycobakterielle sammensetninger og pyrrole derivater som antimycobakterielle sammensetninger
FR2865732B1 (fr) Composes de type hydrazide et leur utilisation dans des compositions pharmaceutiques pour le traitement des maladies cardiovasculaires

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application